Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Akebia Therapeutics (AKBA) Misses Q2 EPS by 19c
August 5, 2021 8:04 AM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.51), $0.19 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $52.9 million versus the consensus estimate of $52.88 million.
"The first half of 2021 has been marked by significant milestones that have further strengthened Akebia's position and the potential market opportunity for vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), setting the stage for an exciting and catalyst-rich year ahead for us. During the quarter, these... More
